Drug Price Trends for ADALIMUMAB-ADAZ(CF) PEN

Average Pharmacy Cost for ADALIMUMAB-ADAZ(CF) PEN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML	61314-0327-20	1588.68646	ML	2025-02-19
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML	61314-0327-20	1588.90220	ML	2025-01-22
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML	61314-0327-20	1590.28426	ML	2024-12-18
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML	61314-0327-20	1589.95972	ML	2024-11-20
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML	61314-0327-20	1592.01806	ML	2024-10-23

Market Analysis and Price Projections for ADALIMUMAB-ADAZ(CF) PEN

Market Overview of Adalimumab

Adalimumab, a recombinant human immunoglobulin G1 monoclonal antibody against tumor necrosis factor (TNF)-alpha, is widely used to treat various inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis among others[1][3][4].

Global Market Trends

The global adalimumab market is expected to grow significantly, driven by several key factors:

• Rise in Autoimmune Diseases: The increasing incidence of autoimmune diseases like psoriatic arthritis, ulcerative colitis, and rheumatoid arthritis is a major driver[3].
• Healthcare Infrastructure: Growing healthcare expenditure and improvements in healthcare infrastructure are also contributing to market growth[3].
• Geriatric Population: The rising geriatric population, which is more prone to chronic ailments, is another significant factor[3].

Market Size and Growth Projections

The adalimumab market was valued at USD 20,912.1 million in 2021 and is projected to reach USD 31,610.01 million by 2029, with a Compound Annual Growth Rate (CAGR) of 5.30% during the forecast period of 2022 to 2029[3].

Biosimilars and Their Impact

The introduction of biosimilars has significantly impacted the adalimumab market. Biosimilars like Hyrimoz (adalimumab-adaz) by Sandoz and YUSIMRY (adalimumab-aqvh) by Coherus are gaining traction due to their cost-effectiveness and similar efficacy to the reference product, Humira[2][4].

Hyrimoz (Adalimumab-Adaz)

• High-Concentration Formulation: Hyrimoz HCF (100 mg/mL) offers a 50% reduction in injection volume compared to the 50 mg/mL concentration, making it more patient-friendly[4].
• Market Approval: Hyrimoz HCF is approved for all indications no longer covered by the regulatory exclusivity for Humira, including rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis[4].
• Pharmacokinetic Studies: Studies have demonstrated the pharmacokinetic comparability between Hyrimoz HCF and Hyrimoz LCF, as well as with the reference product Humira[1].

Pricing Analysis

Current Pricing

The pricing of Hyrimoz (adalimumab-adaz) varies based on the formulation and dosage:

• 40 mg/0.4 mL Syringe: The Wholesale Acquisition Cost (WAC) for Hyrimoz (adalimumab-adaz) 40 mg/0.4 mL syringe is approximately $8,220.61[5].
• 40 mg/0.8 mL Pen: The WAC for the 40 mg/0.8 mL pen is around $812.50[5].

Competitive Pricing

Coherus Biosciences' YUSIMRY (adalimumab-aqvh) is set to launch with an industry-wide lowest list price of $995 per carton for two 40 mg/0.8 mL autoinjectors, which could influence the pricing dynamics of other biosimilars like Hyrimoz[2].

Price Projections

Given the competitive landscape and the growing demand for cost-effective treatments, here are some price projection insights:

Short-Term Projections

• Competition from New Biosimilars: The entry of new biosimilars like YUSIMRY could lead to a slight decrease in prices as companies compete for market share. This might result in a 5-10% reduction in the list price of Hyrimoz over the next year[2][5].

Long-Term Projections

• Market Saturation: As more biosimilars enter the market, the overall pricing is expected to stabilize or decrease further. By 2029, the prices of adalimumab biosimilars, including Hyrimoz, could be 20-30% lower than current levels due to increased competition and market saturation[3].

Regulatory and Market Challenges

Despite the growth potential, the adalimumab market faces several challenges:

• High Manufacturing Costs: The complex nature of the molecule and high manufacturing costs can hinder the growth of biosimilar markets[3].
• Regulatory Hurdles: Strict regulatory processes and the need for extensive clinical trials can delay market entry and affect pricing strategies[3].
• Side Effects and Safety Concerns: Adverse effects associated with adalimumab, such as nausea and dizziness, can impact patient adherence and overall market growth[3].

Key Takeaways

• The adalimumab market is expected to grow significantly due to increasing autoimmune disease incidence and improving healthcare infrastructure.
• Biosimilars like Hyrimoz and YUSIMRY are changing the pricing landscape with their cost-effective offerings.
• Short-term price projections indicate a potential decrease due to competition, while long-term projections suggest further stabilization or reduction in prices.
• Regulatory and manufacturing challenges need to be addressed to fully capitalize on market growth.

FAQs

1. What is the current market size of the adalimumab market? The adalimumab market was valued at USD 20,912.1 million in 2021[3].

2. What is the projected growth rate of the adalimumab market? The market is expected to grow at a CAGR of 5.30% from 2022 to 2029[3].

3. What are the key drivers of the adalimumab market growth? Key drivers include the rise in autoimmune diseases, increasing healthcare expenditure, and the growing geriatric population[3].

4. How does Hyrimoz HCF compare to the standard formulation? Hyrimoz HCF offers a 50% reduction in injection volume compared to the 50 mg/mL concentration, making it more patient-friendly[4].

5. What is the impact of new biosimilars on the pricing of Hyrimoz? New biosimilars like YUSIMRY could lead to a 5-10% reduction in the list price of Hyrimoz in the short term due to increased competition[2][5].

Sources

1. FDA: Clinical/Cross Discipline Team Leader/Division Summary Review - BLA 761071 S-014 Hyrimoz/Adalimumab-adaz[1].
2. Coherus Biosciences: Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh)[2].
3. Data Bridge Market Research: Global Adalimumab Market – Industry Trends and Forecast to 2029[3].
4. Sandoz: Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation in the US[4].
5. California Department of Industrial Relations: Adalimumab Pricing[5].